8-K: Termination of Sales Agreement
8-K: Bionano Announces Effective Date of Reverse Stock Split
8-K: Bionano Genomics Held a Special Meeting of Stockholders
424B3: Prospectus
8-K: Bionano Reports Preliminary Fourth Quarter and Full-Year 2024 Results
SCHEDULE 13G: Others
EFFECT: Others
S-3/A: Registration statement for specified transactions by certain issuers (Amendment)
CORRESP: CORRESP
UPLOAD: Others
8-K: Bionano Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
424B5: Prospectus
S-3: Registration statement for specified transactions by certain issuers
8-K: Bionano Announces Amendment to Senior Secured Convertible Debentures in Debt Restructuring that Improves Cash Runway
DEFA14A: Others
DEFA14A: Others
DEF 14A: Definitive information statements
8-K: Bionano Genomics Held Its 2024 Special Meeting of Stockholders
PRE 14A: Preliminary proxy statements relating to merger or acquisition
10-Q: Q3 2024 Earnings Report